Pfizer's and Bristol-Myers Squibb's ELIQUIS Approved In Europe For Preventing Venous Thromboembolism After Elective Hip Or Knee Replacement

The European Commission has approved ELIQUIS® in the 27 countries of the European Union for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery. This decision marks the first approval for ELIQUIS®, a new oral direct Factor Xa inhibitor being developed by the alliance of Bristol-Myers Squibb Company

and Pfizer Inc.